Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fondaparinux
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous
01
Overview
Fondaparinux is a synthetic anticoagulant classified as a selective factor Xa inhibitor. It is composed of five monomeric sugar units and structurally mimics the antithrombin III (ATIII) binding site found in heparin and heparan sulfate. Fondaparinux works by binding to ATIII, which enhances ATIII’s ability to inhibit activated Factor X (factor Xa), thereby interrupting the blood coagulation cascade and reducing thrombin generation. This results in decreased formation of blood clots. Fondaparinux is primarily indicated for the prevention and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), especially after orthopedic or abdominal surgery, as well as for use in acute coronary syndromes such as unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), and ST segment elevation myocardial infarction (STEMI)[1][2][3][8].
- Brand names
- Arixtra
- Other names
- natural heparin pentasaccharide
02
Targets
ATIII (Antithrombin III)
Beyond the preview
Go deeper on fondaparinux.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fondaparinux.